




ALAIN POL/SPL

● HEAD TO HEAD, p 20


● PRACTICE, p 43

## NEWS

- 1 US specialties list five tests and treatments that doctors and patients can safely avoid  
Most laboratory cancer studies cannot be replicated, study shows
- 2 Regulator tells clinics to treat egg and sperm donors better to boost numbers  
Herbal medicine might be responsible for high incidence of urinary tract cancer in Taiwan  
NHS looks set to save £20m as antipsychotic drug comes off patent
- 3 Virgin Care is set to take over two NHS community health services in Surrey  
Using art to explore the physiology of elite athletes
- 4 Whole genome sequencing fails to predict risk of common diseases  
Wellcome Trust insists on open access to its research



## RESEARCH



### RESEARCH HIGHLIGHTS

- 11 The pick of *BMJ* research papers this week

### RESEARCH NEWS

- 12 All you need to read in the other general journals

### RESEARCH PAPERS

- 13 Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial  
EDIE-2 Trial Investigators group
- 14 Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study  
Nicholas L Mills et al  
● EDITORIAL, p 6
- 15 Association between low functional health literacy and mortality in older adults: longitudinal cohort study  
Sophie Bostock and Andrew Steptoe  
● EDITORIAL, p 7
- 16 Credibility of claims of subgroup effects in randomised controlled trials: systematic review  
SATIRE Investigators Group  
● EDITORIAL, p 8

## COMMENT

### EDITORIALS

- 5 Antibiotic drug research and development  
Jean-Pierre Paccaud  
● ANALYSIS, pp 22, 25
- 6 New guidance for troponin assays  
Adam Timmis  
● RESEARCH, p 14
- 7 Health literacy  
D K Theo Raynor  
● RESEARCH, p 15
- 8 Subgroup analyses  
Andrew D Oxman  
● RESEARCH, p 16
- 9 Interventional neuroradiology to treat hyperacute ischaemic stroke  
Alex M Mortimer et al
- 10 The role of regulation in healthcare  
Richard B Saltman



What next for Monitor? p 10

### FEATURES

- 17 Research paper of the year: interventions to improve health  
Trish Groves
- 18 How the search for new drugs for neglected diseases is paying off  
Academia, industry, and non-profit bodies are partnering to find new ways of treating neglected diseases, Janice Hopkins Tanne reports

### HEAD TO HEAD

- 20 Should we treat lower urinary tract symptoms without a definitive diagnosis?  
Paul Abrams argues no; Julian Shah says yes

### ANALYSIS

- 22 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards  
Anthony So et al
- 25 Challenges of drug resistance in the developing world  
Ramanan Laxminarayan and David Heymann



Drug resistance in the developing world, p 25

Articles appearing in this print journal have already been published on *bmj.com*, and the version in print may have been shortened. *bmj.com* also contains material that is supplementary to articles: this will be indicated in the text (references are given as w1, w2, etc) and be labelled as extra on *bmj.com*.

Please cite all articles by year, volume, and eLocator (rather than page number), eg *BMJ* 2012; 344:d286.

A note on how to cite each article appears at the end of each article, and this is the form the reference will take in PubMed and other indexes.



Azithromycin for trachoma, p 30

## COMMENT

## LETTERS

- 28 Focal liver lesions
- 29 Treating sciatica; Epistaxis
- 30 Trachoma control; Spotlight on climate change
- 31 Dignity in care of older people

## OBSERVATIONS

## YANKEE DOODLING

- 32 How will the US Supreme Court rule on health reform? Douglas Kamerow

## VIEWS AND REVIEWS

## PERSONAL VIEW

- 33 Mathematics medicalises us all  
James Le Fanu

## BETWEEN THE LINES

- 34 Innocent tumours  
Theodore Dalrymple

## MEDICAL CLASSICS

- 34 The Normal Child by Ronald S Illingworth  
Ian Johnston



Illustrations of pathology, p 34

## OBITUARIES

- 35 Vincent "Čensu" Tabone
- 36 Wilfred Ernest Chapman; Robert Andrew Fay; Manjusha Ravindra Gokhale; Jack Gould; Murray Archibald Jackson; Alan Ernest Gerald Pearson; Naveen Premaratne


## LAST WORDS

- 49 Why we should read the *Economist* Des Spence  
The reputation robbing historians Wendy Moore

## EDUCATION

## CLINICAL REVIEW

- 37 Cluster headache  
Alexander D Nesbitt, and Peter J Goadsby



The trigeminovascular reflex, p 37

## PRACTICE

## THERAPEUTICS

- 43 Antimuscarinic drugs to treat overactive bladder  
Dudley Robinson and Linda Cardozo

## 10-MINUTE CONSULTATION

- 46 A scaly rash on the hands H Reddy et al

## ENDGAMES

- 48 Quiz page for doctors in training

## MINERVA

- 50 Urological robotics, and other stories

## FILLER


- 47 On nakedness at work

## Author submissions

### Get published

Have you ever thought about submitting your work to one of the most respected general medical journals in the world? Think no longer—here's your chance. Find out how you can get your research published in the *BMJ* today.

Visit  
[bmj.com/authors](http://bmj.com/authors)



BMJ

The Editor, *BMJ*  
 BMA House, Tavistock Square,  
 London WC1H 9JR  
 Email: editor@bmj.com  
 Tel: +44 (0)20 7387 4410  
 Fax: +44 (0)20 7383 6418  
**BMA MEMBERS' INQUIRIES**  
 Email: membership@bma.org.uk  
 Tel: +44 (0)20 7383 6642  
**BMJ CAREERS ADVERTISING**  
 Email: sales@bmjcareers.com  
 Tel: +44 (0)20 7383 6531  
**DISPLAY ADVERTISING**  
 Email: sales@bmjgroup.com  
 Tel: +44 (0)20 7383 6386  
**REPRINTS**  
 UK/Rest of world  
 Email: ngurneyrandall@bmjgroup.com  
 Tel: +44 (0)20 8445 5825  
 USA  
 Email: mfogler@medicalreprints.com  
 Tel: +1 (856) 489 4446  
**SUBSCRIPTIONS**  
 BMA Members  
 Email: membership@bma.org.uk  
 Tel: +44 (0)20 7383 6642  
 Non-BMA Members  
 Email: support@bmjgroup.com  
 Tel: +44 (0)20 7383 6270  
**OTHER RESOURCES**  
 For all other contacts:  
 resources.bmj.com/bmj/contact-us  
 For advice to authors:  
 resources.bmj.com/bmj/authors  
 To submit an article:  
 submit.bmj.com

The BMJ is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association.

The BMA grants editorial freedom to the Editor of the *BMJ*. The views expressed in the journal are those of the authors and may not necessarily comply with BMA policy. The *BMJ* follows guidelines on editorial independence produced by the World Association of Medical Editors ([www.wame.org/wamestmt.htm#independence](http://www.wame.org/wamestmt.htm#independence)) and the code on good publication practice produced by the Committee on Publication Ethics ([www.publicationethics.org.uk/guidelines/](http://www.publicationethics.org.uk/guidelines/)).

The *BMJ* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury, or damage resulting from the use of the *BMJ* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

©BMJ Publishing Group Ltd 2012  
 All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any other means, electronic, mechanical, photocopying, recording, or otherwise, without prior permission, in writing, of the *BMJ*.

Published weekly. US periodicals class postage paid at Rahway, NJ. Postmaster: send address changes to *BMJ*, c/o Mercury Airfreight International Ltd Inc, 365 Blair Road, Avenel, NJ 07001, USA. \$796.

Weekly  
 Printed by Polestar Limited



DAMIEN HIRST AND SCIENCE LTD. ALL RIGHTS RESERVED. DACS 2012/PHOTO PRUDENCE CUMING ASSOC

## PICTURE OF THE WEEK

Medicalisation and overtreatment have long been a feature of artist Damien Hirst's work, and they are clearly a theme of the Hirst retrospective exhibition that opened at Tate Modern in London last week. *Pharmacy*, pictured here, is a room sized installation, which was first shown in New York in 1992. The exhibition, which brings together key works from over 20 years, runs until 9 September.

## MOST READ ON BMJ.COM

- Safety and efficacy of antibiotics compared with appendicectomy for treatment of uncomplicated acute appendicitis
- White rice consumption and risk of type 2 diabetes
- Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease
- The management of ingrowing toenails
- Risk of cancer in first seven years after metal-on-metal hip replacement compared with other bearings and general population

## MOST COMMENTED ON BMJ.COM

- White rice consumption and risk of type 2 diabetes
- Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting
- Putting patients first
- Emergency contraception
- Bad medicine: modern medicine

## BMJ.COM POLL

This week's poll asks, "Should doctors have a stronger voice in policy on illegal drug use?"

[bmj.com](http://bmj.com) Cast your vote

## RESPONSE OF THE WEEK

**"Obesity is a very real problem but not always recognised by the patient, particularly when suggesting the offspring are obese, overweight, or even fat. I doubt whether many patients like to hear they have cancer, but using med speak such as 'mitotic lesion' may fail to deliver the message. Of course communication takes time, and there is no place for brutality, but patients who have been upset may well show gratitude for openness at follow-up"**



Simon Kenwright, retired physician, Ashford, Kent, in response to "My choice of words" (*BMJ* 2012;344:e1370)



## EDITOR'S CHOICE

## Back to basics with the three Rs

**In India alone, per capita antibiotic use increased by 37% between 2005 and 2010, and in New Delhi in 2003-4 more than 70% of *Escherichia coli* bacteria isolated from the urine of healthy women were resistant to ampicillin and nalidixic acid**

We've known for years that the world is running out of effective antibiotics. What should we do? Epidemiologists Ramanan Laxminarayan and David Heymann contrast the widespread misuse of antibiotics in lower income countries with the undertreatment that contributes to one million deaths of children from pneumonia each year (p 25). In India alone, per capita antibiotic use increased by 37% between 2005 and 2010, and in New Delhi in 2003-4 more than 70% of *Escherichia coli* bacteria isolated from the urine of healthy women were resistant to ampicillin and nalidixic acid. Weak public healthcare and private systems that benefit from drug sales, they say, are making this a very tough nut to crack.

Anthony D So and colleagues lead us into industry's "valley of death," where companies no longer want to take possibly antimicrobial compounds into costly clinical research programmes with uncertain return on investment (p 22). They see salvation through three Rs: sharing resources, risks, and rewards among the private and public research sectors. While companies might once have balked at sharing commercially sensitive data, "the line between precompetitive and competitive data has shifted downstream, leading to unprecedented collaborations," say the authors. Drug development focused on single targets and molecules is too narrow, however, and "we need to get back to the basics of biology—'targeting an organism (bacterium) inside another organism (the human host)'—and give more attention to the potential of resistance arising rapidly."

Jean-Pierre Paccard from the Drugs for Neglected Diseases initiative doubts that current "push" and "pull" incentives for the private sector to develop new

antibiotics will succeed (p 5). Instead, he suggests, antibiotic development might become largely the responsibility of the public sector. Then new antibiotics could be public goods, available to every patient in need at an affordable price. Partnerships with industry would still be important, though, and at the recent annual conference on neglected diseases in Philadelphia, Paccard described numerous successful collaborations (p 18).

Given all this, I was glad that the Head to Head debate asking "should we treat lower urinary tract symptoms without a definitive diagnosis?" wasn't about antibiotics for infections (p 20). Instead, it focuses on a group of common disorders affecting storage and voiding of urine and problems after micturition, and termed, er, "lower urinary tract symptoms." "Unfortunately, the term has been extended to apply to any patient, male or female, young or old, with urinary symptoms," argues Julian Shah. "Terms come into parlance because of the enthusiasm of a particular group [and] symptoms are generally not resolved by 'best guess' medical management." Unless appropriate urodynamic testing shows obstruction, he says, reassurance may suffice and medical treatment may be useless. Indeed, a systematic review found that 43-83% of patients discontinue medical treatment within 30 days. Paul Abrams, on the other hand, asserts that invasive investigations are often unnecessary and impractical and that lifestyle interventions, behaviour modification, and drugs for these symptoms are neither risky nor expensive. Guidance from the UK National Institute for Health and Clinical Excellence seems to agree with him. Who's right?

**Trish Groves, deputy editor, BMJ**  
tgroves@bmj.com

Cite this as: *BMJ* 2012;344:e2654

► To receive Editor's Choice by email each week, visit [bmj.com/cgi/customalert](http://bmj.com/cgi/customalert)

## Twitter

► Follow Trish Groves at [twitter.com/trishd](https://twitter.com/trishd) and the *BMJ* at [twitter.com/bmj\\_latest](https://twitter.com/bmj_latest)

# When was your last update?

## BMJ Masterclasses

[masterclasses.bmj.com](http://masterclasses.bmj.com)

